Docherty KF, Jhund PS, Claggett B, et al. - In this exploratory analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure randomized clinical trial that involved 4,744 patients, researchers estimated the projected long-term dapagliflozin-induced treatment impacts in patients suffering from heart failure and reduced ejection fraction (HFrEF) over the duration of a patient’s lifetime. Patients received dapagliflozin, 10 mg, once daily vs placebo in addition to standard therapy. Time to first hospitalization for heart failure, urgent heart failure visit necessitating intravenous therapy, or cardiovascular death was set as the primary composite outcome. Findings demonstrated that clinically meaningful gains in extrapolated event-free and overall survival were achieved with dapagliflozin use in patients with HFrEF.